Rani Therapeutics Files 8-K: Agreements & Equity Sales

Ticker: RANI · Form: 8-K · Filed: May 20, 2025 · CIK: 1856725

Rani Therapeutics Holdings, Inc. 8-K Filing Summary
FieldDetail
CompanyRani Therapeutics Holdings, Inc. (RANI)
Form Type8-K
Filed DateMay 20, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, equity-sale, financials

TL;DR

Rani Therapeutics dropped an 8-K on 5/20 - new deals and stock sales.

AI Summary

On May 20, 2025, Rani Therapeutics Holdings, Inc. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 2051 Ringwood Avenue, San Jose, California.

Why It Matters

This 8-K filing indicates significant corporate actions, including new agreements and equity transactions, which could impact the company's financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.

Key Numbers

  • 001-40672 — SEC File Number (Identifies the company's filing with the SEC.)
  • 25966414 — Film Number (Internal SEC processing number.)

Key Players & Entities

  • Rani Therapeutics Holdings, Inc. (company) — Registrant
  • May 20, 2025 (date) — Date of earliest event reported
  • 2051 Ringwood Avenue, San Jose, California 95131 (location) — Principal executive offices
  • Delaware (jurisdiction) — State of incorporation

FAQ

What type of material definitive agreement was entered into by Rani Therapeutics Holdings, Inc.?

The filing does not specify the nature of the material definitive agreement, only that one was entered into.

What was the date of the earliest event reported in this 8-K filing?

The earliest event reported was on May 20, 2025.

Where are Rani Therapeutics Holdings, Inc.'s principal executive offices located?

The principal executive offices are located at 2051 Ringwood Avenue, San Jose, California 95131.

What is the SEC file number for Rani Therapeutics Holdings, Inc.?

The SEC file number is 001-40672.

What are the key items reported in this 8-K filing?

The key items reported are Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, and Financial Statements and Exhibits.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 20, 2025 regarding Rani Therapeutics Holdings, Inc. (RANI).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.